Role of nanotechnology in therapeutics and diagnosis of Alzheimer’s disease

Abstract

Alzheimer's disease refers to a pathological topography accompanied by the loss of neurons in the brain regions including entorhinal cortex and hippocampus, resulting in memory impairment, cognitive dysfunction, behavioural problems, and difficulties in activities of daily living that ultimately lead to mortality. This disease typically affects the elderly population. Even if the underlying pathophysiological mechanisms are unclear, Alzheimer's disease is unquestionably associated with dysfunction in the cholinergic system, resulting in a decreased level of acetylcholine in specific brain regions, including the entorhinal cortex and hippocampus. Although significant progress has been made in understanding the molecular and cellular causes of Alzheimer's disease, there is presently no medication available to reduce or stop the loss of brain cells. As the number of individuals with Alzheimer's disease continues to rise, there is a pressing need to develop ways for early diagnosis and offer viable treatments to avert a public health crisis. In recent years, nanoparticles have been seriously studied as a diagnostic and therapeutic tool for Alzheimer's disease. Here, we discuss the recent growth in nanoparticles for Alzheimer's disease diagnosis and treatment.